Back to Journals » Journal of Pain Research » Volume 12

Tapentadol: a new option for the treatment of cancer and noncancer pain

Authors Dickenson AH, Kress HG

Received 8 October 2018

Accepted for publication 27 November 2018

Published 16 May 2019 Volume 2019:12 Pages 1509—1511

DOI https://doi.org/10.2147/JPR.S190171

Checked for plagiarism Yes

Editor who approved publication: Dr Katherine Hanlon


Anthony H Dickenson,1 Hans G Kress2

1Neuroscience, Physiology and Pharmacology, University College London, London WC1E6BT, UK; 2Department of Special Anaesthesia and Pain Medicine, Medical University, AKH of Vienna, Vienna, Austria

The last years have witnessed major advances in the knowledge of the basic mechanisms underlying the onset and the chronification of pain. In particular, it has emerged that pain signaling and modulatory mechanisms change following physiopathological events, such as the two major types of pain, neuropathic and inflammatory pains. Very different chemical events and ion channel changes, respectively, underlie these pains at peripheral levels, so treatments have to differ. Low back pain and cancer pain can be one or the other or a combination of these different mechanisms, so-called mixed pains. The final pain experience is a combination of all these peripheral and central events, but within the central nervous system, the pain controlling systems are more common so that therapies acting on central modulation can span a range of pain conditions. Descending controls link the brain back to the spinal cord, where noradrenaline (NRI) is a key inhibitory transmitter in pain control in these pathways. Descending controls run from the brain to the spinal cord and can be gaged in patients – the balance between excitations and facilitations’ shift to the latter in persistent pain states, reinforcing pain transmission.1


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]